Yoshiyama Annie 4

What Happened

• Annie Yoshiyama, Senior Vice President, Finance at Allogene Therapeutics (ALLO), reported the sale of 9,586 shares on April 21, 2026. The reported weighted-average price was $2.31, for proceeds of about $22,144. The filing identifies this as a sell-to-cover to satisfy tax withholding tied to the vesting of restricted stock units (RSUs), not a discretionary sale.

Key Details

• Transaction date: April 21, 2026; Form 4 filed April 23, 2026 (appears timely).
• Reported price: weighted average $2.31; shares sold in multiple trades from $2.31 to $2.33.
• Shares sold: 9,586; reported proceeds ≈ $22,144.
• Reason: Sell-to-cover to satisfy tax withholding on vested RSUs (mandated under issuer's equity plan).
• Shares owned after transaction: not specified in the provided filing summary.
• Related note: filing footnote indicates inclusion of 3,781 shares acquired March 15, 2026 via employee stock purchase plan (ESPP).

Context

• Sell-to-cover transactions are routine tax-withholding actions when RSUs vest and typically do not reflect an insider’s discretionary decision about the company’s prospects.
• The filing shows a straightforward tax-withholding sale (transaction code S with explanatory footnote), not an options exercise, gift, or a strategic open-market purchase.